107 results
Page 2 of 6
8-K
EX-99.1
x9507te2j ayj2xt8q73
19 Dec 22
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
4:49pm
8-K
EX-99.1
7su53 bhpak4n
9 Nov 22
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
4:11pm
8-K
EX-99.1
gxa3oyjlu06pn3zleg
3 Oct 22
Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of
9:00am
8-K
EX-99.1
joyjq6
10 Aug 22
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
4:06pm
8-K
EX-99.1
qk923ivpi
20 Jul 22
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
8:01am
8-K
EX-99.1
gnj5js
10 May 22
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
4:01pm
8-K
EX-99.1
4a2g3xslb59
30 Mar 22
Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering
5:24pm
424B5
gn06oyln69kx1d0zd6m
30 Mar 22
Prospectus supplement for primary offering
5:21pm
8-K
EX-99.1
ykv0f nxnuxw87g
28 Mar 22
Soleno Therapeutics Announces Proposed Underwritten Public Offering
4:59pm
424B5
9tcrho20gbf2irqw
28 Mar 22
Prospectus supplement for primary offering
4:53pm
8-K
EX-99.1
u4squ rn68an8
24 Jan 22
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
8:06am
8-K
EX-99.1
1ksw0or6oh5h8isp gy
10 Nov 21
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results
4:16pm
424B5
y3ghjhm8fgft
16 Jul 21
Prospectus supplement for primary offering
4:07pm
8-K
EX-99.1
nrfjs
5 May 21
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results
4:01pm